With diverse applications in diagnostic imaging, theragnostics, and targeted therapy, radiopharmaceuticals are gradually tapping into an ocean of unlimited opportunities
By 2030, the radiopharmaceutical market size is expected to grow to $12.18B. In 2023, POINT Biopharma topped the list among radiopharma companies with a market cap of $726.88B followed by Novartis with a market cap of $235.92B, RayzeBio with $102.14B
PharmaShots brings a condensed report on the Top 20 Radiopharma Companies based on Market Cap.
Market Cap: $14.29M
Founded Year: 2021
Total Employees: ~50
Headquarters: Victoria, Australia
Stock Exchange: ASX
Radiopharm Theranostic is an Australian biotech company indulged in the pre-clinical or clinical-stage development of radiopharmaceuticals for the diagnosis and treatment of various indications, including cancer
The company has a vast pipeline of products under clinical development, including RAD101 for Brain Metastases and RAD301 for Pancreatic Cancer. Moreover, under its pre-clinical development pipeline, the company currently has RAD202 for Breast and Gastric Cancer, RAD402 for Prostate Cancer, RAD206 for Breast and Lung Cancer, etc.
In Mar 2023, Radiopharm reported the acquisition of Pharma15 Corp
Market Cap: $28.78M
Founded Year: 2009
Total Employees: ~31
Headquarters: Oslo, Norway
Stock Exchange: OSE
A biotech company, Nordic Nanovector, develops and commercializes antibody-radionuclide conjugates to address major unmet medical needs
Betalutin, among the company’s lead assets, is a novel CD37-targeting antibody-radionuclide-conjugate being developed for the treatment of patients with NHL. Other radiotherapies under the company’s pipeline include Humalutin and Alpha37
In Jun 2023, Nordic Nanovector signed an agreement to merge with Thor Medical
Market Cap: $28.78M
Founded Year: 2001
Total Employees: ~60
Headquarters: Kawasaki, Japan
Stock Exchange: TYO
OncoTherapy Science discovers and develops molecular-targeted anti-cancer drugs, cancer therapies, and cancer-specific serum diagnostic markers to improve clinical benefits among patients. The company develops its products using cancer-specific genes highly expressed in cancer cells
The company develops a variety of products including, low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines. OncoTherapy had earlier reported a significant anti-cancer activity of OTSA101 in mouse xenograft models
Moreover, in terms of its radio pharma business, the company is currently developing OTSA101, an anti-FZD10 antibody that specifically binds to FZD10 in cancer cells, for the treatment of Synovial Sarcoma
Market Cap: $29.39M
Founded Year: 2004
Total Employees: ~4
Headquarters: Texas, United States
Stock Exchange: OTCMKTS
A clinical-stage biotech company, QSam Biosciences develops and commercializes targeted therapeutic radiopharmaceuticals for the treatment of cancers in adults and paediatric patients
CycloSam (Samarium-153 DOTMP), a bone-targeting radiopharmaceutical developed by Iso Therapeutics, is among the company’s lead radiopharma assets. The company is currently evaluating CycloSam under clinical trial for the treatment of bone cancer and related diseases
In Nov 2023, Telix Pharmaceuticals signed a conditional term sheet to acquire QSam Biosciences for its lead asset CycloSam
Market Cap: $34.37M
Founded Year: 2001
Total Employees: ~20
Headquarters: Tokyo, Japan
Stock Exchange: TYO
A Japanese biotech firm, Perseus Proteomics’ primary business idea is to discover and develop monoclonal antibodies. The company leverages the hybridoma method (animal immunes) and the phase display method (human antibodies) to develop antibodies for a wide range of indications
Currently, the company’s pipeline focuses on the development of PPMX-T002 and PPMX-T004, both of which are anti-cancer drugs with an antibody targeting CDH3 connected with a radioisotope yttrium 90 (90Y). Moreover, the company is also indulged in developing PPMX-T003 for Blood Cancers, including Polycythaemia Vera and Aggressive NK-Cell Leukaemia
In Dec 2023, Perseus Proteomics reported the P-I clinical trial results evaluating the safety and efficacy of PPMX-T003 in Polycythaemia Vera patients
Market Cap: $73M
Founded Year: 1991
Total Employees: ~200
Headquarters: Beijing, China
Stock Exchange: NASDAQ
A US-based pharmaceutical company, CASI Pharmaceuticals is a renowned biopharma company that develops and commercializes pharmaceutical therapies across the globe, including the US and China
Zevalin, a CD20-directed radiotherapeutic antibody, is a lead asset to the company developed under the radiopharma segment. Earlier in Feb 2019, CASI Pharmaceuticals received the exclusive license to Zevalin from Acrotech Biopharma
In Jul 2023, CASI Pharmaceuticals reported the acquisition of all rights and global intellectual property rights to Cleave Therapeutics’ CB-5339, a novel VCP/p97 inhibitor
Market Cap: $118.15M
Founded Year: 1996
Total Employees: ~15
Headquarters: New Jersey, United States
Stock Exchange: NASDAQ
A late clinical-stage biopharma company, Cellectar Biosciences is a company that discovers and develops proprietary drugs through its Phospholipid Drug Conjugate (PDC) delivery platform
The company mainly targets cancer indications by developing PDC targeting cancer cells to deliver an effective and safe off-target effect. Under its product pipeline, the company has CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells along with proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets
In Oct 2023, Cellectar secured four patents for its PDC delivery platform and iopofosine (131I) across Europe, Australia, and Canada
Market Cap: $204.84M
Founded Year: 1897
Total Employees: ~800
Headquarters: Seoul, Korea
Stock Exchange: KRX
Dong Wha Pharmaceutical is a Korean pharma company that discovers and develops pharmaceutical products covering therapy areas, including antipyretics, analgesics, and antibiotics for cardiovascular, dermatological, and alimentary ailments
As an asset under its radiopharma business, the company is currently developing Milican (DW-166HC) injections for Hepatocellular Carcinoma and Haemophiliac Arthritis
In Aug 2023, Dong Wha Pharma reported the acquisition of TRUNG SON Pharma, a Vietnamese Pharmacy Chain, for an aggregate of ~$301M
Market Cap: $226.71M
Founded Year: 2000
Total Employees: ~50
Headquarters: New York, United States
Stock Exchange: NYSE
A clinical stage targeted radiotherapy company; Actinium Pharmaceuticals focuses on developing therapeutics for patients with unmet needs. Strengthened by its Antibody Warhead Enabling (AWE) technology Platform, the company manages to produce highly selective and potent antibody radiation conjugates
Actinium’s lead candidate is Iomab-B (CD45) (apamistamab-I-131) currently in P-III, indicated for BMT conditioning. In P-I, Actinium has Iomab-ACT (CD45), Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, Actimab-A (CD33) and Venetoclax with HMA.
In Feb 2023, Actinium Pharmaceuticals signed a Cooperative Research and Development Agreement (CRADA) with the NCI to develop Actimab-A for the treatment of Acute Myeloid Leukaemia (AML) and other Hematologic Malignancies
Market Cap: $499.84M
Founded Year: 2010
Total Employees: ~40
Headquarters: Sydney, Australia
Stock Exchange: ASX
A clinical stage radiopharma company, Clarity Pharmaceuticals discovers and develops radiopharmaceuticals for the treatment of various therapy areas with Oncology as its primary focus
Targeted Copper Theragnostic (TCT) is the company’s lead asset developed based on its SAR Technology Platform for the treatment of children and adults with cancer. Clarity’s pipeline is lined up with a series of products for the treatment of various indications including Prostate Cancer (SAR-bisPSMA, SAR-BBN) and Neuroblastoma (SARTATE)
In Apr 2023, Clarity Pharmaceuticals received $6.7M as R&D Tax Incentive Refund as part of the Australian Federal Government’s R&D Tax Incentive Program
Sources:
Annual reports
SEC Filings
Press releases
Company websites
Market Cap Source: Google Finance (28th Feb 2023)
Currency Conversion: X-Rates (28th Feb 2023)
Note:
All market caps were marked on 28th Feb 2023
Related Posts: Top 20 Radiopharma Companies Based on Market Cap
For full report, reach out to us at connect@pharmashots.com
